According to a recent LinkedIn post from Touchlight, the company plans to participate in the ASGCT 2026 conference in Boston from May 11–15, where it intends to engage with attendees about its cell‑free DNA technologies, including mbDNA and Custom Circles. The post suggests Touchlight will use its presence at booth 1334 to highlight how these platforms aim to address limitations associated with plasmid DNA and support faster development timelines for gene and cell therapy programs.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights a focus on positioning its cell‑free DNA manufacturing solutions as enabling technologies for therapy developers seeking to accelerate pipelines. For investors, this emphasis on conference engagement and technical differentiation may signal continued efforts to deepen relationships with biopharma partners, which could influence future collaboration opportunities and Touchlight’s competitive standing in the DNA manufacturing segment of the gene and cell therapy supply chain.